Chemoprevention of colorectal carcinogenesis

International Journal of Clinical Oncology

Volumn 7, Issue 1, 2002, Pages 2-26

  Umar, A ^a   Viner, J L ^a   Richmond, E ^a   Anderson, W F ^a   Hawk, E T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer prevention; Celecoxib; Colorectal carcinoma; Cyclooxygenase; Molecular targeting; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ACETYLSALICYLIC ACID; ANGIOSTATIN; BALSALAZIDE; BATIMASTAT; BOWMAN BIRK INHIBITOR; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ENDOSTATIN; FLURBIPROFEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMATINIB; INDOMETACIN; KETOPROFEN; MITOMYCIN C; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PIOGLITAZONE; PIROXICAM; ROFECOXIB; SEMAXANIB; SULINDAC; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

CANCER DIAGNOSIS; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; DIET THERAPY; DIETARY FIBER; DRUG MECHANISM; FLUORESCENCE SPECTROSCOPY; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REFLECTOMETRY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036220296     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200001     Document Type: Review

References (399)

1. Cancer statistics, 2001
2. Risk biomarkers and current strategies for cancer chemoprevention
3. Approaches to prevention of epithelial cancer during the preneoplastic period
4. Cancer chemoprevention progress and promise
5. President's address. The polyp-cancer sequence in the large bowel
6. A genetic model for colorectal tumorigenesis
7. Molecular changes in the Ki-ras and APC genes in colorectal adenomas and carcinomas arising in the same patient
8. Identification of c-MYC as a target of the APC pathway
9. The role of the E-cadherin/catenin complex in gastrointestinal cancer
10. Molecular interactions in the Vogelstein model of colorectal carcinoma
11. Regulation of cell death protease caspase-9 by phosphorylation
12. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
13. p53, the cellular gatekeeper for growth and division
14. Genetic alterations during colorectal tumor development
15. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
16. Genetic pathways in colorectal and other cancers
17. Biomarkers as surrogates for cancer development
18. Chemoprevention in hereditary colorectal cancer syndromes
19. Scope and methods of prevention
20. The precancerous changes in the rectum and colon
21. Natural history of untreated colonic polyps
22. Polypectomy via the fiberoptic colonoscopy removal of neoplasms beyond reach of the sigmoidoscope
23. Endoscopic polypectomy. Therapeutic and clinicopathologic aspects
24. Prevention of colorectal cancer by colonoscopic polypectomy
25. The effect of fecal occult-blood screening on the incidence of colorectal cancer
26. Colorectal cancer and nonsteroidal anti-inflammatory drugs
27. Aberrant crypt foci of the colon as precursors of adenoma and cancer
28. Colorectal polyps and their relationship to cancer
29. Cumulative incidence of metachronous colorectal cancer
30. Colonoscopy: A review of its yield for cancers and adenomas by indication
31. Incidence of adenomas after curative resection for colorectal cancer
32. The Nurses' Health study: A cohort of US women followed since 1976
33. The Nurses' Health study: 20-Year contribution to the understanding of health among women
34. Tobacco, colorectal cancer, and adenomas: A review of the evidence
35. Physical activity, obesity, and risk of colorectal adenoma in women (United States)
36. Parity and other reproductive factors and risk of adenomatous polyps of the distal colorectum (United States)
37. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States)
38. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
39. Leisure-time physical activity, body size, and colon cancer in women
40. The American Cancer Society Prospective study
41. Cancer mortality and wood dust exposure among participants in the American Cancer Society Cancer Prevention Study-II (CPS-II)
42. Intake of fat, meat, and fiber in relation to risk of colon cancer in men
43. Physical activity, obesity, and risk for colon cancer and adenoma in men
44. Dietary fiber and distal colorectal adenoma in men
45. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States)
46. Vegetables, fruit, and colon cancer in the Iowa Women's Health study
47. The association of drinking water source and chlorination by-products with cancer incidence among postmenopausal women in Iowa: A prospective cohort study
48. Diet and risk of colon cancer in a large prospective study of older women: An analysis stratified on family history (Iowa, United States)
49. A prospective cohort study of intake of calcium, vitamin D, and other micronutrients in relation to incidence of rectal cancer among postmenopausal women
50. Alcohol consumption and colon and rectal cancer in postmenopausal women
51. A large-scale prospective cohort study on diet and cancer in The Netherlands
52. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer
53. Fermented dairy products, calcium, and colorectal cancer in The Netherlands Cohort study
54. A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in The Netherlands
55. Cholecystectomy and colorectal cancer: Evidence from a cohort study on diet and cancer
56. A prospective cohort study on the relation between meat consumption and the risk of colon cancer
57. Consumption of black tea and cancer risk: A prospective cohort study
58. Prospective study on alcohol consumption and the risk of cancer of the colon and rectum in the Netherlands
59. Diet, lifestyle, and colon cancer
60. Vegetables, fruit, and cancer prevention: A review
61. Natural agents in the prevention of cancer. Part 1: Human chemoprevention trials
62. Natural agents in the prevention of cancer, part two: Preclinical data and chemoprevention for common cancers
63. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas
64. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas
65. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: A randomised intervention trial
66. Dietary fiber and coronary artery disease
67. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer
68. Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer
69. Calcium, vitamin D, and colorectal cancer: A review of the epidemiologic evidence
70. Role of calcium in colon cancer prevention: Experimental and clinical studies
71. Calcium supplements for the prevention of colorectal adenomas
72. Chemo- and dietary prevention of colorectal cancer
73. Chemoprevention of colorectal cancer: Role of antioxidant vitamins
74. Nutrition and cancer of the respiratory and digestive tract: Results from observational and chemoprevention studies
75. Dietary intake of specific carotenoids and vitamins A, C, and E, and prevalence of colorectal adenomas
76. Vitamin supplements and cancer risk: The epidemiologic evidence
77. Multivitamin use, folate, and colon cancer in women in the Nurses' Health study
78. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality
79. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas
80. Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps
81. A clinical trial of antioxidant vitamins to prevent colorectal adenoma
82. Growth and recurrence of colorectal polyps: A double-blind 3-year intervention with calcium and antioxidants
83. A comparison of prospective and retrospective assessments of diet in a study of colorectal cancer
84. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: Results from a controlled trial (Finland)
85. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study - Design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants
86. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial
87. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer
88. Serum selenium and subsequent risk of cancer among Finnish men and women
89. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps
90. Serum selenium and colonic neoplastic risk
91. Folate and carcinogenesis: An integrated scheme
92. Nutritional factors in colorectal cancer risk: A case-control study in Majorca
93. Folate intake and carcinogenesis of the colon and rectum
94. Alcohol and nutrients in relation to colon cancer in middle-aged adults
95. Selected micronutrient intake and the risk of colorectal cancer
96. Nutritional status of folate and colon cancer risk: Evidence from NHANES I epidemiologic follow-up study
97. Folate, methionine, and alcohol intake and risk of colorectal adenoma
98. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men
99. Folate and alcohol intakes: Related or independent roles in the adenoma-carcinoma sequence?
100. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: An example of gene-environment interactions in colorectal tumorigenesis
101. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer
102. Chemoprevention of colorectal cancer
103. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis
104. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study
105. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis
106. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: Effect of folate supplementation
107. Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis
108. Effects of folate supplementation on two provisional molecular markers of colon cancer: A prospective, randomized trial
109. Progress in cancer chemoprevention
110. Ornithine decarboxylase as a target for chemoprevention
111. Development of difluoromethylornithine (DFMO) as a chemoprevention agent
112. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse
113. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment
114. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: Reduced incidence of dimethylhydrazine-induced colon tumors in mice
115. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil
116. Comparison of the effects of an ornithine decarboxylase inhibitor on the intestinal epithelium and on intestinal tumors
117. Effects of timing of administration and dose of difluoromethylornithine on rat colonic carcinogenesis
118. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon
119. Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat
120. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon
121. Effect of the chemopreventive agents piroxicam and D,L-alpha-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis
122. Ornithine decarboxylase activity in the rat and human colon
123. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa
124. Ornithine decarboxylase and polyamines in familial adenomatous polyposis
125. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma
126. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer
127. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine
128. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine
129. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps
130. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention
131. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer
132. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet
133. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination
134. Reduced growth rate of dimethylhydrazine-induced colon tumors in rats
135. Selenium and difluoromethylornithine additively inhibit DMH-induced distal colon tumor formation in rats fed a fiber-free diet
136. Effects of cyclosporine and alpha-difluoromethylornithine on the growth of mouse colon cancer in vitro
137. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine
138. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
139. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention
140. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas
141. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
142. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder
143. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder
144. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
145. COX-2 is expressed in human pulmonary, colonic, and mammary tumors
146. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy
147. Cyclooxygenase-2 is overexpressed in human cervical cancer
148. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo
149. Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398
150. COX-2 expression in retinoblastoma
151. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations
152. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
153. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2
154. Reduced COX-2 protein in colorectal cancer with defective mismatch repair
155. Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex
156. The role of COX-2 in intestinal cancer
157. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
158. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis
159. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
160. The relationship between cyclooxygenase-2 expression and colorectal cancer
161. Cyclooxygenase-2 as a target for prevention of colorectal cancer
162. Transcriptional regulation of cyclooxygenase-2 gene expression: Novel effects of nonsteroidal anti-inflammatory drugs
163. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism
164. Differential expression of cyclooxygenase 2 in human colorectal cancer
165. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
166. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398
167. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
168. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas
169. Meloxicam inhibits the growth of colorectal cancer cells
170. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
171. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas
172. Cyclooxygenase-2 expression in colorectal cancer liver metastases
173. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas
174. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms
175. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
176. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer
177. Regulation of cyclooxygenase-2 pathway by HER2 receptor
178. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers
179. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice
180. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
181. Cyclooxygenase-2 expression in Barrett's esophagus
182. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
183. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey
184. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
185. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
186. Cyclooxygenase-2 expression in human esophageal carcinoma
187. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
188. Cyclooxygenase-2 pathway correlates with vegf expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
189. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398
190. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
191. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
192. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: Possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases
193. Cyclooxygenase-2 expression in hepatocellular carcinoma
194. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors
195. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
196. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
197. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
198. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
199. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression
200. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells
201. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer
202. Expression of cyclooxygenase-2 in prostate carcinoma
203. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
204. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression
205. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin
206. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
207. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
208. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells
209. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma
210. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus
211. Expression of cyclooxygenase-2 in human gastric carcinoma
212. Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours
213. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma
214. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas
215. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability
216. Effects of sulindac on sporadic colorectal adenomatous polyps
217. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: A population-based study
218. Use and safety of aspirin in the chemoprevention of colorectal cancer
219. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
220. The clinical potential of cyclooxygenase-2-specific inhibitors
221. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
222. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
223. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
224. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
225. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
226. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
227. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent anti-tumor activity in mice
228. Combinatorial chemoprevention of intestinal neoplasia
229. Postmenopausal hormone use and risk for colorectal cancer and adenoma
230. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
231. Reproductive factors, oral contraceptive use, and risk of colorectal cancer
232. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case-Control study
233. Hormone replacement therapy and the risk of colorectal cancer: A meta-analysis
234. Benefits and challenges of hormone replacement therapy
235. The mutagenicity of bile acids using a fluctuation test
236. Nakahara memorial lecture. Application of the mechanisms of nutritional carcinogenesis to the prevention of cancer
237. A factor in the increased risk of colorectal cancer due to ingestion of animal fat is inhibition of colon epithelial cell glutathione S-transferase, an enzyme that detoxifies mutagens
238. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium
239. Colonic mucosal proliferation is related to serum deoxycholic acid levels
240. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: Suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue
241. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats
242. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid
243. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats
244. Prolonged administration of bile salts for gallstone dissolution and its effect on rectal epithelial cell proliferation
245. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
246. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
247. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction
248. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
249. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
250. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
251. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
252. Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury
253. Protection against dimethylhydrazine-induced adenomatous tumors of the mouse colon by the dietary addition of an extract of soybeans containing the Bowman-Birk protease inhibitor
254. Bowman-Birk soybean protease inhibitor as an anticarcinogen
255. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor
256. Protease inhibitors on trial for inflammatory bowel disease
257. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia
258. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial
259. Protease inhibitors in oral carcinogenesis and chemoprevention
260. Matrilysin in early stage intestinal tumorigenesis
261. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
262. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis
263. Lovastatin induces apoptosis in malignant mesothelioma cells
264. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice
265. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells
266. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
267. Do statins cause cancer? A meta-analysis of large randomized clinical trials
268. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
269. Genetic and cellular changes in colorectal cancer: Proposed targets of chemopreventive agents
270. Cancer chemoprevention and therapy by monoterpenes
271. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation
272. Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents
273. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol
274. Prevention and therapy of cancer by dietary monoterpenes
275. Prospective study of the frequency and size distribution of polyps missed by colonoscopy
276. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies
277. The identification of monoclonality in human aberrant crypt foci
278. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate
279. High-resolution chromoendoscopy for the diagnosis of diminutive colon polyps: Implications for colon cancer screening
280. Colonic polyp differentiation using time-resolved autofluorescence spectroscopy
281. Ex vivo optical properties of human colon tissue
282. Detection of preinvasive cancer cells
283. Optical coherence tomography
284. High-resolution endoscopic imaging of the GI tract using optical coherence tomography
285. Feasibility of optical coherence tomography for high-resolution imaging of human gastrointestinal tract malignancies
286. In vivo endoscopic optical biopsy with optical coherence tomography
287. High resolution imaging of the upper respiratory tract with optical coherence tomography: A feasibility study
288. New technology for high-speed and high-resolution optical coherence tomography
289. Ultrahigh-resolution ophthalmic optical coherence tomography
290. Scanning single-mode fiber optic catheter-endoscope for optical coherence tomography
291. High resolution in vivo intra-arterial imaging with optical coherence tomography
292. In vivo endoscopic OCT imaging of precancer and cancer states of human mucosa
293. Endoscopic applications of optical coherent tomography
294. Fluorescence spectroscopy of neoplastic and non-neoplastic tissues
295. Light-induced fluorescence spectroscopy of adenomas, adenocarcinomas and non-neoplastic mucosa in human colon. I. In vitro measurements
296. Use of colonoscopy to screen asymptomatic adults for colorectal cancer
297. The best screening test for colorectal cancer - A personal choice
298. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men
299. Dietary fiber and the risk of colorectal cancer and adenoma in women
300. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women
301. A prospective study of family history and the risk of colorectal cancer
302. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women
303. Risk factors for fatal colon cancer in a large prospective study
304. Aspirin use and risk of fatal cancer
305. Aspirin use and reduced risk of fatal colon cancer
306. Risk factors for self-reported colon polyps
307. Relationship of diet to risk of colorectal adenoma in men
308. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
309. Chemoprevention of colorectal cancer
310. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
311. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis
312. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy
313. Perillyl alcohol: Applications in oncology
314. Pre-clinical development of farnesyltransferase inhihitors
315. Tyrosine kinase inhibitors - Solid cancers
316. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
317. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
318. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
319. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
320. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
321. Promising new developments in cancer chemotherapy
322. Effects of dietary wheat bran fiber on rectal epithelial cell proliferation in patients with resection for colorectal cancers
323. Wheat fibre, lactulose and rectal mucosal proliferation in individuals with a family history of colorectal cancer
324. Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps
325. The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps
326. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis
327. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps
328. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas
329. Design and baseline characteristics of study participants in the Wheat Bran Fiber trial
330. Progress report: The Arizona phase III study of the effect of wheat bran fiber on recurrence of adenomatous colon polyps
331. Chemo-prevention of metachronous adenomas of the large bowel: Design and interim results of a randomized trial of calcium and fibre
332. Design of the Women's Health Initiative clinical trial and observational study
333. Calcium supplementation modifies the relative amounts of bile acids in bile and affects key aspects of human colon physiology
334. Randomized trial of the effect of calcium supplementation on fecal risk factors for colorectal cancer
335. Supplemental calcium suppresses colonic mucosal ornithine decarboxylase activity in elderly patients with adenomatous polyps
336. Effect of calcium supplementation on rectal epithelial hyperproliferation in intestinal bypass subjects
337. Oral calcium suppresses increased rectal epithelial proliferation of persons at risk of colorectal cancer
338. Effect of added dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer
339. Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis
340. Long-term effects of dietary calcium on risk markers for colon cancer in patients with familial polyposis
341. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer
342. Effect of calcium supplementation on mucosal cell proliferation in high risk patients for colon cancer
343. Reduction of mucosal crypt cell proliferation in patients with colorectal adenomatous polyps by dietary calcium supplementation
344. Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma
345. Calcium and colorectal epithelial cell proliferation: A preliminary randomized, double-blinded, placebo-controlled clinical trial
346. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: A randomized, double-blinded, placebo-controlled clinical trial
347. Calcium supplementation and rectal mucosal proliferation: A randomized controlled trial
348. The effect of calcium supplements on rectal mucosal proliferation
349. Effect of longterm placebo controlled calcium supplementation on sigmoidal cell proliferation in patients with sporadic adenomatous polyps
350. Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: A randomized controlled trial
351. Effects of milk and milk products on rectal mucosal cell proliferation in humans
352. Calcium chemoprevention in colorectal cancer
353. The relationship between faecal bile acid profile with or without supplementation with calcium and antioxidants on recurrence and growth of colorectal polyps
354. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
355. Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis
356. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors
357. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis
358. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy
359. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment
360. Sulindac in familial adenomatous polyposis
361. Sulindac therapy of colorectal polyps in familial adenomatous polyposis
362. Is sulindac effective for familial adenomatous polyposis?
363. Effects of long-term sulindac therapy on colonic polyposis
364. Sulindac suppression of colorectal polyps in Gardner's syndrome
365. Sulindac for polyposis of the colon
366. Sulindac treatment for familial polyposis coli
367. Sulindac for polyposis of the colon
368. Non-steriodal anti-inflammatory drug use is associated with reduced risk of colorectal adenomas: A prospective study
369. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas
370. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
371. Aspirin use, cancer, and polyps of the large bowel
372. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease
373. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
374. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin
375. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study
376. Aspirin use and p53 expression in colorectal cancer
377. Drugs and colon cancer
378. Association between coronary heart disease and cancers of the breast, prostate, and colon
379. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma
380. Rheumatoid arthritis and the risk of malignancy
381. Aspirin and colorectal cancer
382. Risk factors of colorectal cancer in inflammatory bowel disease
383. Low incidence of colorectal cancer in patients with rheumatoid arthritis
384. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
385. Diseases preceding colon cancer. A case-control study among veterans
386. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study
387. Aspirin use and reduced risk of fatal colon cancer
388. Aspirin and colorectal cancer
389. Aspirin and the prevention of colorectal cancer: A review of the evidence
390. Aspirin and colorectal cancer: The Leisure World cohort revisited
391. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer study
392. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
393. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis
394. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis
395. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
396. Sulindac causes regression of rectal polyps in familial adenomatous polyposis